

**Wednesday Feb 12th**

**18.00-20.00 Welcome reception Cancer Center Karolinska, Floor 5**

**Thursday Feb 13th, venue Sune Bergström auditorium at Bioclinicum, Karolinska University Hospital, Solna**

07.45-	Registration at Bioclinicum, outside of Sune Bergström auditorium.
08.20-08.30	Welcome, information
	<b>Immunotherapy</b> Chair: Eric Raymond, University of Paris
08.30-09.00	Rolf Kiessling, Karolinska Institutet Immune therapy of cancer; recent advances and challenges
09.00-09.30	This session has been sponsored by MSD Pedro Farrajota Neves da Silva, Karolinska University Hospital From lab bench to bedside: Immunotherapy in head and neck squamous cell carcinoma (HNSCC)
09.30-09.55	Per Straten, University of Copenhagen The exercise of TAMing the immune system
09.55-10.15	<b>Coffee break</b> <b>Breast cancer</b> Chair: Andrea Bonetti, Mater Salutaris Hospital Legnago (Verona, ITALY).
10.15-10.40	Jonas Bergh, Karolinska Institutet General overview of breast cancer with special attention to prognostication and prediction during tumour progression
10.40-11.05	Charlotta Dabrosin, Linköping University The inflammatory microenvironment affects breast cancer progression
11.05-11.30	Theo Foukakis, Karolinska Institutet Deciphering the role of immune microenvironment in breast cancer: expression patterns, prognostic/predictive value and therapeutic implications
11.30-12.00	<b>Presentation of selected abstracts</b> Santiago Parpal, Sprint Bioscience Modulation of the tumor inflammatory landscape by Vps34 inhibitors as basis for combination immunotherapy Margot S.F. Roeten, Amsterdam UMC

	Evaluation of the proteasome inhibitor Ixazomib effectivity against primary pediatric acute leukemia cells and Bortezomib-resistant leukemia cells
12.00-12.45	<b>Lunch</b>
	<b>Ovarian cancer and Prostate cancer</b> Chair: Paola Perego, Istituto Tumori, Milan
12.45-13.10	Filippo Cortesi, University Medical Center Hamburg, Eppendorf  Tumor-specific iNKT cell plasticity - Prostate <i>versus</i> Colon
13.10-13.35	Sten Nilsson, Karolinska Institutet  Treatment of disseminated prostate cancer
13.35-14.00	Martina Bazzaro, University of Minnesota  Novel strategies for treatment of late stage ovarian cancer
14.00-14.25	Paula Cunnea, Imperial College, London  Novel approaches to personalised therapy for epithelial ovarian cancer
14.25-14.55	<b>Coffee break</b>
	<b>Individualised therapy</b> Chair: Rolf Lewensohn, Karolinska Institutet
14.55-15.25	Jan-Olov Sandberg, Roche  Implementation of precision medicine in oncology - challenges and opportunities
15.25-15.50	Andrea Bonetti, Mater Salutis Hospital Legnago (Verona, ITALY)  Next generation sequencing in clinical diagnosis
15.50-16.15	Triona Ní Chonghaile, Royal College of Surgeons in Ireland, Ireland  BH3 profiling to functionally interrogate cell death pathways and identify combination treatments
16.15-16.40	Bo Franzén, Karolinska Institutet  Molecular diagnostics using fine needle tumour aspirates for cancer treatment decisions
16.40-17.05	Joseph Ciccolini, University of Marseille  Improving PK/PD profiles of anticancer agents with nanoparticles
19.00- 21.00	<b>Conference dinner, Restaurant Solliden, Skansen,</b>  <i>Transfer bus departs at 18.15 from Elite Hotel Carolina Tower and has a pick-up at Elite Hotel Palace.</i>  <i>Transfer bus back to the Elite hotel Carolina Tower and Elite hotel Palace at 21:15</i>

**Friday Feb 14th**

	<b>DNA repair</b> Chair: Frits Peters, University Medical Center, Amsterdam
08.30-08.55	Thomas Helleday, Karolinska Institutet  MTHFD2, targeting the DDR at the crossroad of metabolism
08.55-09.20	Vincenzo Costanzo, Fondazione Istituto FIRC, Milan  Understanding and treating DNA repair and replication defects due to BRCA1/2 deficiency
09.20-9.45	Duncan Jodrell, University of Cambridge  Synergy between ATR Inhibitors and Gemcitabine to Induce Pancreatic Ductal Adenocarcinoma Regression
09.45-10.15	<b>Coffee break</b>
	<b>Novel therapeutics</b>  Chair: Etienne Chatelut, Institut Universitaire du Cancer Toulouse- Uncopole  Padraig D'arcy, Linköping University
10.15-10.35	This session has been sponsored by Astra Zeneca  Simon Ekman, Karolinska Institutet  Clinical activity and resistance mechanisms of osimertinib in patients with EGFR-mutated advanced NSCLC
10.35-11.00	Elias Arnér, Karolinska Institutet  The selenoprotein thioredoxin reductase as target for cancer therapeutics
11.00-11.25	Lars-Gunnar Larsson, Karolinska Institutet  Selective targeting of the interaction between MYC and MAX
11.25-11.50	Klas Wiman, Karolinska Institutet  Pharmacological reactivation of mutant p53
11.50-12.10	<b>Presentation of selected abstracts</b>  Mjriam Capula, Pisa Science Foundation  Role of miRNA-21 and YAP in mechanical memory and chemoresistance of pancreatic cancer cells  Sean Rudd, Karolinska Institutet  Targeting SAMHD1 to enhance existing cancer therapies
12.10-13.00	<b>Lunch</b>
	<b>Tumor Models</b>

	Chair: Elisa Giovanetti, University Medical Center, Amsterdam
13.00-13.25	Oded Kopper, Hebrew University of Jerusalem  Novel ovarian cancer organoid platforms for research and personalized medicine
13.25-13.50	Mårten Fryknäs, Uppsala University  Multicellular tumor cultures and identification of context - dependent vulnerabilities
13.50-14.15	Leoni Kunz Schughart, Technical University, Dresden  Using the spheroid control probability assay for combination therapy
14.15-14.40	Martin Michaelis, University of Kent  Drug-induced heterogeneity associated with acquired resistance formation
14.40-15.00	<b>Coffee break</b>
	<b>Head and Neck cancer</b>  Chairs: Tina Dalianis, Karolinska Institutet  Eva Munck af Rosenschöld-Wikland, Karolinska Institutet
15.00-15.25	Paolo Bossi, University of Brescia (EORTC-Head&Neck Group)  Looking for new combinations for immunotherapeutics in head and neck cancer
15.25-15.50	Rieneke van der Ven, VUmc, Amsterdam  Immunology and head and neck cancer: from bench to bedside
15.50-16.15	Laura Locati, Istituto Nazionale dei Tumori, Milan (EORTC-Head & Neck group)  Immunoheterogeneity of HPV-related oropharynx cancer and patients' outcome
16.15-17.05	<b>Presentation of selected abstracts</b>  Farina Hellmann, University of Muenster  External Model Validation of a Population Pharmacokinetic Model for Doxorubicin in a Cohort of Ewing Sarcoma Patients  Ariane Rocha Bartolomeu, São Paulo State University  The effects of major bioactive coffee compounds against mouse colon carcinogenesis: miRNA profile modulation  Emilie Vinolo, Science SPRL  The EurOPDX Research Infrastructure: improving and facilitating European and worldwide cancer research with patient-derived xenografts  Timothy Isaac Johnson, University of Cambridge  Quantifying cell cycle-dependent drug sensitivities: combining a novel synchronisation method with high-throughput screening
17.05-	<b>POSTER VIEWING, catering</b>

## Saturday Feb 15th

	<b>Medicinal Chemistry</b> Chairs: Andrew Westwell, University of Cardiff Georg Hempel, University of Münster
09.00-09.25	Caroline Low, Drug design consultant, London, UK Using open source tools for kickstarting MAP4K4 drug discovery - lessons learnt
09.25-09.50	Johannes Kirchmair University of Vienna, Vienna PAIN(S) relievers for pharmacologists: How in silico tools can help to flag compounds that are prone to cause false outcomes in biological assays
09.50-10.15	Barbara Parrino, University of Palermo Marine alkaloid analogs as valuable tools to fight cancer
10.15-10.30	Markus Joerger, Department of Medical Oncology & Hematology, Cantonal Hospital, Switzerland Safety and pharmacokinetics of a novel nano-sized micellar formulation of docetaxel
10.30-10.45	<b>Coffee break</b>
10.45-11.10	Per Artursson, Uppsala University Impact of intracellular unbound drug concentration on target engagement, pharmacological response and drug-drug interactions
11.10-11.35	Christian Rolfo, University of Maryland School of Medicine Liquid biopsies
11.35-12.20	Burger-Kelland lecture Nadia Zaffaroni and Paola Perego, Istituto Tumori, Milan
12.20-12.30	Poster prize and closure